PremiumRatingsBuy Rating for Surgery Partners: Strong Revenue Growth, Strategic Developments, and Market Opportunities Surgery Partners price target lowered to $35 from $40 at Benchmark Surgery Partners Reports Strong Revenue Growth for 2024 PremiumPre-EarningsSGRY Earnings Report this Week: Is It a Buy, Ahead of Earnings? BofA moves to No Rating on Surgery Partners after Bain offer Surgery Partners says committee to review $25.75 per share buyout proposal PremiumThe FlySurgery Partners price target lowered to $35 from $49 at RBC Capital Surgery Partners post-earnings selloff overdone, says Macquarie Surgery Partners price target lowered to $31 from $32 at Barclays 
